BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 8, 2026
Home » Topics » Regulatory

Regulatory
Regulatory RSS Feed RSS

Capsules in blister packs

Better incentives needed to tackle antibiotic resistance

Nov. 22, 2021
By Mari Serebrov
Even as antimicrobial resistance is expected to continue to grow, the development of much-needed novel antibiotics and antifungals remains trapped in a catch-22 in which funding is available for early stage research but not necessarily for the translational work necessary to bring the drugs to market.
Read More
Glucose monitoring

PK? OK! Provention moving ahead with teplizumab’s phase III

Nov. 22, 2021
By Lee Landenberger
The FDA has removed an obstacle to Provention Bio Inc.’s development of teplizumab in treating type 1 diabetes.
Read More

Regulatory actions for Nov. 22, 2021

Nov. 22, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Antengene, Biogen, BMS, Gilead, Gracell, Moderna, Pfizer, Roche.
Read More
Moderna COVID-19 vaccine

CDC, FDA take action on COVID-19 boosters

Nov. 19, 2021
By Randy Osborne
The FDA amended emergency use authorizations (EUAs) for the Moderna Inc. COVID-19 vaccine as well as the shot from Pfizer Inc. and Biontech SE. A single booster dose was green-lighted for people 18 years and older at least six months after finishing the primary regimen with either of the vaccines, or at least two months after getting the Johnson & Johnson shot. 
Read More
FDA Approved seal

First drug is approved for achondroplasia

Nov. 19, 2021
By Jennifer Boggs and Lee Landenberger
Biomarin Pharmaceutical Inc.’s data supporting the use of Voxzogo (vosoritide) in children with the most common form of dwarfism proved compelling for the FDA, which cleared the modified C-type natriuretic peptide as the first treatment for the rare genetic disease affecting bone growth.
Read More
Medtronic-Micra-11-12.png

FDA wary of risk of perforation associated with Medtronic’s Micra leadless pacemaker

Nov. 19, 2021
By Mark McCarty
Dublin-based Medtronic plc’s Micra pacemaker was a groundbreaking device when the FDA approved the leadless pacemaker in 2016, thanks to the elimination of the hazards associated with pacemaker leads. However, the FDA said recently that the risks associated with cardiac perforation with leadless pacemakers, such as tamponade or death, might be higher with the Micra than with pacemakers with leads.
Read More
Product image with microscopic close up

Istar reports first implants of Miniject glaucoma device after CE mark approval

Nov. 19, 2021
By Nuala Moran
LONDON – The first commercial implantations of Istar Medical SA’s minimally invasive Miniject supraciliary glaucoma drainage device have taken place in Germany, following European CE approval for the product.
Read More

Regulatory actions for Nov. 19, 2021

Nov. 19, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Datar Cancer Genetics.
Read More

Regulatory actions for Nov. 19, 2021

Nov. 19, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Armata, Heron, Longeveron, Mediwound, Merck, Molecular Templates, Verrica, Vitro.
Read More
EU flags in front of the Berlaymont building

Surveillance of pre-MDR devices in EU to transition from legacy regulatory system

Nov. 18, 2021
By Mark McCarty
The European Union’s Medical Device Coordination Group (MDCG) continues to churn out guidances for the new Medical Device Regulations (MDRs), but there are several nagging questions about devices granted market access under the legacy system. MDCG has clarified that these devices will be subject to postmarket surveillance requirements under the MDR system rather than the previous system, although it is not a simple process to determine when this approach does and does not apply.
Read More
Previous 1 2 … 624 625 626 627 628 629 630 631 632 … 1376 1377 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Illustration of brain and brain waves, concept of focal seizure

    Hyperexcitability may be joint problem in epilepsy, dementia

    BioWorld
    The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
  • 3D rendering of an antibody drug conjugate

    ‘Target-high but uptake-defective’ state identified in ADC resistance

    BioWorld
    Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing